Black checkmark with a sparkle and a curved line underneath on a white background.
Company

FEMASYS INC

Ticker
FEMY
Sector
Industry
Report date
November 14, 2026
Valye AI Score

80

Very high visibility
Recent developments
Recent developments summary

Recent developments for Femasys include regulatory progress with FDA clearance for FemBloc, expansion of commercial partnerships to increase fertility care access, financing activities to support growth, and stock price movements reflecting market reactions.

Recent developments:
  • Femasys stock rose 7% amid broader biotech sector gains, reflecting positive market sentiment [N1].
  • The company doubled enrollment sites for its FemBloc pivotal study, advancing clinical development [N1].
  • Femasys tapped SandsRx Pharmacy to coordinate medications for FemaSeed patients, enhancing treatment delivery [N1].
  • Femasys expanded fertility portfolio adoption through Minnesota Women's Care, broadening clinical reach [N1].
  • The company partnered with CapexMD and UNC Health to expand access to its FemaSeed fertility portfolio [N1].
  • Femasys regained Nasdaq compliance and continues focusing on its reproductive health pipeline [N5].
  • FDA cleared Femasys' modular PMA pathway for FemBloc non-surgical birth control technology, supporting regulatory progress [N3].
  • Femasys expanded its European commercial footprint with a Swiss partner for FemBloc, FemaSeed, and other products [N6].
  • The company entered a $30 million private placement with potential proceeds up to $90 million to fund development and expansion [N8].
Overview

Femasys Inc operates in the reproductive health sector, developing and commercializing fertility care products. Its key offerings include FemBloc, a non-surgical permanent birth control system, and FemaSeed, a fertility treatment portfolio. The company has advanced regulatory approvals, including FDA clearance for FemBloc's modular PMA pathway and CE Mark certification. Commercial expansion efforts include partnerships with fertility clinics and healthcare providers across the U.S. and Europe. Financing activities have included convertible notes and public offerings to support product development and commercial growth. The company reported a net loss in the latest quarter but maintains strong liquidity. Risks include potential dilution from convertible securities and ongoing litigation related to financing agreements.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Femasys Inc is a reproductive health company focused on fertility care products such as FemBloc and FemaSeed. The company has received FDA clearance for FemBloc's modular PMA pathway and expanded its commercial footprint in Europe. It has formed multiple partnerships to enhance access to its fertility portfolio. Femasys has engaged in several financing rounds, including convertible notes and public offerings, which carry dilution risks. As of September 30, 2026, the company reported $23.9 million in cash and equivalents, strong liquidity ratios, and a net loss of $4.56 million for the quarter. Ongoing litigation related to convertible notes could affect financial condition. Recent developments include regulatory progress, clinical study expansion, and Nasdaq compliance restoration.

Scenarios for FEMY

Bull case model:

Femasys has demonstrated progress in regulatory approvals, including FDA clearance for FemBloc's modular PMA pathway and CE Mark certification, which support commercialization efforts. Expansion of commercial partnerships and increased enrollment sites for pivotal studies indicate growing market adoption. The company's strong liquidity position provides resources for ongoing product development and market expansion. Strategic collaborations in the U.S. and Europe broaden its commercial footprint. These factors collectively support the company's ability to advance its reproductive health pipeline and increase access to its fertility care products.

Bear case model:

Femasys faces significant dilution risk from convertible notes and warrants, which could materially increase shares outstanding and depress stock value. The company reported a net loss and ongoing litigation related to its 2025 Notes financing, which could adversely affect liquidity and financial condition. Regulatory and clinical development risks remain, including the need to secure full FDA approvals and successfully complete pivotal studies. Market competition in fertility care and reproductive health is intense, and the company must sustain commercial partnerships and reimbursement support to maintain growth. Financial and operational challenges could constrain execution and shareholder value.

Moat:

Femasys' moat is anchored in its proprietary fertility care technologies, including FemBloc's non-surgical permanent birth control system and the FemaSeed fertility portfolio. Regulatory clearances such as FDA modular PMA pathway and CE Mark certification provide barriers to entry. Strategic partnerships with fertility clinics and healthcare providers enhance market access and adoption. The company's focus on reproductive health and first-line fertility treatments positions it in a specialized niche with clinical and reimbursement support, including AMA CPT code approval. However, the moat is challenged by the need for continued regulatory approvals, clinical validation, and competitive pressures in the fertility care market.

Risks overview
Risks summary
The most significant risks for Femasys include potential shareholder dilution from convertible securities, ongoing litigation related to financing agreements, and regulatory and clinical development uncertainties that could impact financial condition and business execution.
Risks details:

• Dilution Risk from Convertible Notes and Warrants: The company has issued $12 million senior secured convertible notes with PIK interest and multiple warrants that could significantly dilute existing shareholders if converted or exercised. This dilution risk is compounded by anti-dilution provisions and additional financing activities.
• Ongoing Litigation Related to 2025 Notes: Femasys is involved in litigation alleging that an August 2026 financing triggered an obligation to repay the 2025 Notes. An adverse outcome could require substantial cash payments, reduce operational funds, and increase financing needs.
• Regulatory and Clinical Development Risks: The company must secure full FDA approvals and successfully complete pivotal clinical studies for its products such as FemBloc. Delays or failures could impact commercialization and market acceptance.
• Financial Performance and Liquidity: Despite strong liquidity ratios as of September 30, 2026, the company reported a net loss and depends on continued financing and operational execution to sustain development and commercial activities.

FINAL FORECAST FOR FEMY

Final take one line
Femasys exhibits very high visibility with detailed regulatory, commercial, and financial disclosures, supported by extensive recent news and SEC filings.
Final take 12 to 24 month view

Business trends: Expansion of fertility care portfolio adoption, regulatory progress for FemBloc, and strategic partnerships to broaden market access.
Execution milestones: Advancement of FemBloc pivotal study enrollment, FDA modular PMA clearance, and European commercial expansion.
Key risks: Dilution from convertible securities, ongoing litigation related to financing, regulatory approval uncertainties, and financial performance challenges.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

80
LLM visibility overview
LLM Visibility known facts
  • Femasys Inc is focused on reproductive health and fertility care products, including FemBloc, a non-surgical permanent birth control technology, and FemaSeed, a fertility treatment portfolio.
  • The company has received FDA clearance for a modular PMA pathway for FemBloc, advancing it toward U.S. approval.
  • Femasys has expanded its European commercial footprint through a Swiss partner for FemBloc, FemaSeed, and other portfolio products.
  • The company has formed partnerships with various fertility care providers and organizations, including SandsRx Pharmacy, Minnesota Women's Care, CapexMD, UNC Health, and Carolinas Fertility Institute to expand access and adoption of its fertility portfolio.
  • Femasys has engaged in multiple financing activities, including a $30 million private placement with potential proceeds up to $90 million, an $8 million public offering, and a $4.5 million offering through public sale and private placement of shares.
  • The company issued $12 million senior secured convertible notes in November 2025 with an 8.5% PIK interest rate, maturing in November 2035, convertible into common stock shares, with associated warrants potentially diluting existing shareholders.
  • As of September 30, 2026, Femasys had $23.9 million in cash and cash equivalents, current assets of $31.2 million, current liabilities of $3.6 million, a current ratio of 8.67, and a cash ratio of 6.64, indicating strong liquidity.
  • The company reported a net loss of approximately $4.56 million and basic and diluted EPS of -$0.53 for the quarter ended September 30, 2026.
  • There is ongoing litigation related to the 2025 Notes financing, with plaintiffs seeking approximately $3.1 million plus interest and fees, which could impact liquidity and financial condition.
  • Femasys regained Nasdaq compliance and continues to focus on its reproductive health pipeline.
  • The company has received AMA CPT Editorial Panel approval for a new Category III CPT code for FemaSeed ITI, supporting reimbursement and adoption.
  • Recent news highlights include stock price movements, clinical trial progress, regulatory approvals, and commercial expansion efforts.
  • The company’s capital structure includes convertible notes and warrants that could cause significant dilution to existing shareholders if converted or exercised.
  • Femasys has increased enrollment sites for its FemBloc pivotal study and is actively advancing clinical and regulatory milestones.
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-10-20 | www.nasdaq.com | Biotech Stocks Move Higher: MBRX Gains 15%, FEMY Rises 7%, RVMD Advances 7%, MYGN Surges Over 40% | https://www.nasdaq.com/articles/biotech-stocks-move-higher-mbrx-gains-15-femy-rises-7-rvmd-advances-7-mygn-surges-over-40
  • N2 | 2026-09-11 | www.nasdaq.com | Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials | https://www.nasdaq.com/articles/weekly-buzz-jnj-wins-fda-nod-axgn-hcwb-strike-deals-roiv-azn-gpcr-lead-clinical-trials
  • N3 | 2026-08-28 | www.nasdaq.com | Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal | https://www.nasdaq.com/articles/weekly-buzz-gild-roiv-win-fda-nod-bhvn-lly-strike-deal-syre-misses-monotherapy-goal
  • N4 | 2026-07-22 | www.nasdaq.com | Top Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filing | https://www.nasdaq.com/articles/top-biotech-gainers-wgrx-rebrands-pvla-nears-fda-milestone-asbp-track-nda-filing
  • N5 | 2026-06-25 | www.nasdaq.com | Femasys Regains Nasdaq Compliance, Focuses On Reproductive Health Pipeline | https://www.nasdaq.com/articles/femasys-regains-nasdaq-compliance-focuses-reproductive-health-pipeline
  • N6 | 2026-02-03 | www.globenewswire.com | Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products | https://globenewswire.com/news-release/2026/02/03/3231201/0/en/Femasys-Expands-European-Commercial-Footprint-with-Swiss-Partner-for-FemBloc-FemaSeed-and-Portfolio-Products.html
  • N7 | 2025-11-21 | www.nasdaq.com | Laidlaw & Co. Initiates Coverage of Femasys (FEMY) with Buy Recommendation | https://www.nasdaq.com/articles/laidlaw-co-initiates-coverage-femasys-femy-buy-recommendation
  • N8 | 2025-08-27 | www.nasdaq.com | Femasys Prices $8 Mln Public Offering To Fund Product Development And Commercial Expansion | https://www.nasdaq.com/articles/femasys-prices-8-mln-public-offering-fund-product-development-and-commercial-expansion
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine